PrEP and ART Clinical Trial
Official title:
The Thai Red Cross AIDS Research Centre
Objective
1. To determine pharmacokinetic (PK) DDI between GAHT and ARVs used as PrEP and ART among
TGW
2. To evaluate ARV adherence among TGW
GAHT will be initiated on week 0. ARVs, either PrEP or ART, will be initiated on week 3. GAHT
will then be withheld on week 5, and restart at week 8.
GAHT: Oral estradiol valerate 2 mg once daily and cyproterone acetate 25 mg once daily, which
are the treatment of choice for GAHT in the TRC-ARC's Tangerine Community Health Center, will
be provided to all participants.
PrEP and ART regimen: Generic fixed-dose combination of TDF 300 mg and FTC 200 mg will be
used for PrEP and a generic fixed-dose combination of TDF 300 mg, FTC 200 mg and efavirenz
600 mg will be used for ART as recommended in the 2017 Thailand National Guidelines on
HIV/AIDS Treatment and Prevention.
;